Project Grant HT9425261E328
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $840K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90033, USA
Similar Awards
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $2,490,000.00 to the University of Southern California (USC) to develop a VAV2 antisense oligonucleotide therapeutic for amyotrophic lateral sclerosis (ALS). The award period runs from March 1, 2025 to February 28, 2027. USC, a leading private research university, will leverage its expertise in advanced biomedical research to pursue this innovative...
- Federal Grant Award Summary Emory University's Office of Sponsored Programs received an $840,000 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective April 1, 2026, through March 31, 2028. The award funds research titled "Repurposing Approved Drugs as First-in-Class Disruptors of the P38/MK2 Complex to Suppress Neuroinflammation in ALS," which investigates therapeutic approaches to amyotrophic...
- Federal Grant Award Summary The University of Miami's Office of Research Administration - School of Medicine Division received a $1.0 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded September 30, 2026, with an ultimate completion date of September 29, 2029. The project, titled "Immunoassay Development and Validation of HDGFL2-CE as a Monitoring and Susceptibility/Risk Biomarker in ALS,"...
- Award Summary The University of Southern California's Department of Contracts and Grants Division received a $871,500 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025 through August 31, 2028. The award funds research into YAP (Yes-Associated Protein) inhibition as a therapeutic approach for treating vestibular schwannoma, a benign tumor of the vestibular nerve. This research aligns...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded $831,722 through its Military Medical Research and Development program (CFDA 12.420) to Aristotle University of Thessaloniki's Special Account for Research Funds on June 15, 2026, for a two-year project completion deadline of June 14, 2028. The award supports research on oxidized-protein targeted degradation as a first-in-class therapeutic strategy to combat oxidative damage in amyotrophic lateral sclerosis (ALS). This project...
- Federal Grant Award Summary Award Details: The Defense Health Agency (DHA) awarded University of California, Davis a $2.8 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective April 1, 2026, through March 31, 2029. The award supports development of a consistently intelligible brain-computer interface (BCI) voice synthesis system designed to restore communication capabilities for individuals with amyotrophic lateral sclerosis (ALS). Products and...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded The Washington University Office of Sponsored Research Services a Project Grant of $840,000 under the Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026, through May 31, 2028. This award supports investigative research examining hyperphosphorylation of tau serine 262 as a novel biomarker and therapeutic target in amyotrophic lateral sclerosis (ALS). The research addresses the DHA's mission...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $993,283 Project Grant to The Regents of the University of California, San Francisco under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025 through August 31, 2027. The award supports research into the proteomic determinants and components of progression in multiple sclerosis. This research initiative aligns with the DHA's mission to transform healthcare for service members...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded UCLA a $799,999 Project Grant effective May 1, 2026, through April 30, 2030, under the Military Medical Research and Development program (CFDA 12.420). The project, titled "From H & E to HRD: Linking Morphometry, Clinical, and Molecular Data for Drug Response Prediction," supports biomedical research designed to advance medical solutions for Service Members and the military population. This award represents...
- Federal Grant Award Summary New York University School of Medicine has received a $2.54 million Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2025 through July 31, 2028. The award supports research and development activities focused on advancing a novel therapeutic strategy for amyotrophic lateral sclerosis (ALS) treatment through investigation of the RAGE/DIAPH1 axis. As a premier academic medical...